Ladose

Quick links to important sections

Ladose

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ladose

What is Ladose?

Ladose is a pharmaceutical medication that contains the active substance fluoxetine. It belongs to a category of drugs known as Selective Serotonin Reuptake Inhibitors (SSRIs). This medication is primarily used to address various conditions related to mental health and emotional well-being.

Mechanism of Action

The human brain utilizes various chemical messengers, known as neurotransmitters, to regulate mood and communication between nerve cells. One of these essential chemicals is serotonin.

In individuals experiencing certain mood-related conditions, there may be an imbalance or a functional deficiency in the levels of serotonin available in the brain. Ladose works by inhibiting the reabsorption (reuptake) of serotonin into the nerve cells. By blocking this process, the medication increases the concentration of serotonin in the spaces between neurons (the synaptic cleft), which can help improve mood and emotional stability over time.

Primary Indications

Ladose is typically utilized in the management of several clinical conditions, including:

  • Major Depressive Disorder: It is used to alleviate the persistent feelings of sadness and loss of interest associated with clinical depression.
  • Obsessive-Compulsive Disorder (OCD): It helps manage the repetitive thoughts and behaviors characteristic of this condition.
  • Bulimia Nervosa: It is used as a specialized component in the treatment of this eating disorder to help reduce binge-eating and purging activities.
  • Panic Disorder: It may be used to reduce the frequency and intensity of panic attacks.

Therapeutic Expectations

It is important to understand that Ladose does not produce an immediate effect. Because the medication works by gradually altering the chemical balance in the brain, it often takes several weeks of consistent use before a person begins to notice a significant improvement in their symptoms. The progression of the treatment is usually monitored by healthcare professionals to evaluate the individual's response to the therapy.

Regulatory References

  1. Fluoxetine DailyMed Label (FDA)

What side effects are possible with Ladose?

Possible side effects and safety information

The regulatory profile for Ladose (Fluoxetine) classifies possible adverse reactions by frequency and the body system affected, based on official prescribing documents. These classifications define the drug's safety characteristics without providing clinical advice.

Frequency-Classified Adverse Reactions

The most frequently documented effects in regulatory sources fall into the Very Common and Common categories:

  • Very Common: These typically include Headache, Nausea, Insomnia, Diarrhea, and Fatigue.
  • Common: Adverse reactions classified as common include Anxiety, Nervousness, Decreased Appetite, Somnolence, Abnormal Dreams, Tremor, Dizziness, Dry Mouth, Rash, Sweating (Hyperhidrosis), and Sexual Dysfunction.

Adverse reactions are officially categorized across various System-Organ Classes, including Gastrointestinal Disorders, Nervous System Disorders, and Psychiatric Disorders.

Serious Safety Information and Constraints

Official labeling documents significant risks that require caution. These serious adverse reactions include the potential for Serotonin Syndrome, Abnormal Bleeding/Hemorrhage, and rare but severe dermatological events such as Stevens-Johnson Syndrome. Furthermore, warnings concerning increased risk of Suicidal Thinking and Behavior apply to children, adolescents, and young adults, particularly at the start of treatment or following dose changes.

Specific safety constraints are noted for certain populations. Clearance is reduced in individuals with hepatic impairment, necessitating alternative considerations for use. The medicine is strictly Contraindicated for concurrent use with Monoamine Oxidase Inhibitors (MAOIs).

Overdose and Emergency Response

An overdose of Ladose (fluoxetine) is officially documented to present with a range of symptoms, primarily affecting the Central Nervous System (CNS) and cardiovascular system. Documented clinical manifestations often include CNS effects such as seizures, somnolence (drowsiness), tremor, agitation, and hypomania, alongside gastrointestinal symptoms like nausea and vomiting. The cardiovascular system may exhibit signs such as sinus tachycardia.

Official regulatory information emphasizes that an overdose carries the potential for severe, life-threatening outcomes. These risks include the development of Serotonin Syndrome and serious cardiac toxicity, specifically QT interval prolongation and ventricular arrhythmias. Fatalities have been reported, particularly in cases involving the ingestion of multiple drugs. Furthermore, patients with hepatic impairment may experience prolonged drug elimination, a factor noted in overdose management.

Due to the risk of severe complications, official government guidance mandates that an individual seek immediate medical attention or contact emergency services for any suspected overdose or the manifestation of severe symptoms like collapse or convulsions. Management is strictly symptomatic and supportive treatment, as no specific antidote is known. Continuous cardiac monitoring is a required component of observation, and procedures like the administration of activated charcoal may be considered by medical professionals. This mandated immediate response is crucial given the absence of a specific counteracting agent for fluoxetine toxicity.

Therapeutic Uses of Ladose

What Ladose Treats: Main Uses and Benefits

Ladose (Fluoxetine) is commonly used across multiple therapeutic areas involving certain distressing symptoms that create noticeable functional strain. The medication is applied in clinical settings that involve acute or unstable symptom patterns, and it is used in areas where short-term symptom management is appropriate, providing supportive relief during difficult episodes by easing distress.

“It is commonly used when short-term symptomatic assistance is needed and supports the patient during difficult episodes by easing distress.”

Its therapeutic scope helps address symptom clusters related to persistent low mood in Major Depressive Disorder (MDD), the intrusive thoughts of Obsessive-Compulsive Disorder (OCD), the behavioral patterns of Bulimia Nervosa, and acute anxiety manifestations like Panic Disorder. It is also considered relevant for the management of the severe, cyclical mood changes of Premenstrual Dysphoric Disorder (PMDD) and certain Treatment Resistant conditions. The use supports general well-being and assists with maintaining functional stability in conditions where symptoms may intensify temporarily.

Ladose is also applied as an adjunct treatment (combined with another specific medication) for conditions such as depressive episodes associated with Bipolar I Disorder.


Quick Fact: Relief for Recurrent Symptom Patterns Ladose is commonly used to help manage the frequency and intensity of unwanted, recurrent thoughts (obsessions) and the repetitive, ritualistic behaviors they trigger, assisting with daily functional stability.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Ladose?

Ladose (Fluoxetine) eligibility is determined by specific regulatory criteria addressing absolute prohibitions, approved age groups, and existing health conditions. This information reflects requirements from governmental authorities like the FDA and EMA.


Contraindications

Ladose is contraindicated in patients with a known hypersensitivity to fluoxetine or any component of the formulation. It must not be used concurrently with certain Monoamine Oxidase Inhibitors (MAOIs), Pimozide, Thioridazine, or related MAO-inhibiting drugs like Linezolid, due to the risk of severe reactions. Specific washout periods are required when transitioning between these medications.


Age-Based Eligibility

Use is established for adults for all labeled indications. For pediatric patients, Ladose is approved for Obsessive-Compulsive Disorder (OCD) from age 7 and Major Depressive Disorder (MDD) from age 8. Safety and effectiveness have not been established in children under 7 years of age for any approved indication.


Conditional Use and Restrictions

Certain patient populations require caution or conditional use. This includes individuals with hepatic impairment, where a lower or less frequent dosage may be needed, and those with severe renal failure, where use may be not recommended by some regulators. Restrictions also apply to patients with a history of seizures or those with risk factors for QT prolongation.

Regarding reproductive status, use during pregnancy is permitted only if the potential benefit justifies the potential risks to the fetus. Breastfeeding is not recommended.

What should I know about interactions with other medicines?

Ladose (Fluoxetine) interactions are defined by mandatory prohibitions and specific timing constraints documented in regulatory labels, reflecting its pharmacokinetic and pharmacodynamic activity.

Regulatory Prohibitions and Timing Rules

Co-administration with Monoamine Oxidase Inhibitors (MAOIs), including Linezolid and Intravenous Methylene Blue, is strictly contraindicated due to the risk of Serotonin Syndrome. Combination with Pimozide or Thioridazine is also prohibited due to documented risks of QTc interval prolongation.

Timing rules are mandatory when transitioning between MAOIs and Ladose. A minimum of 5 weeks must pass after discontinuing Ladose before starting an MAOI. Conversely, Ladose should not be started within 14 days of stopping an MAOI.

Pharmacokinetic and Pharmacodynamic Effects

Ladose is officially classified as a potent inhibitor of the CYP2D6 enzyme. This pharmacokinetic interference can significantly increase the exposure and plasma concentration of co-administered drugs primarily metabolized by CYP2D6, such as Tricyclic Antidepressants or specific Antiarrhythmics.

Pharmacodynamic interactions include the risk of Serotonin Syndrome when combined with other serotonergic agents (e.g., Triptans, Tryptophan, St. John’s Wort). Additionally, co-administration with drugs that interfere with hemostasis, such as NSAIDs or Warfarin, potentiates the documented risk of bleeding.

Mechanism of Action

How Ladose Works: Mechanism of Action

Ladose (fluoxetine) acts by targeting core regulatory systems in the central nervous system to modulate overactive signaling patterns. Its pharmacodynamic action is concentrated in two primary mechanistic steps, leading to time-dependent alterations in neuronal pathway activity.

Selective Blockade of Serotonin Reuptake

Ladose functions as a Selective Serotonin Reuptake Inhibitor (SSRI). Its initial molecular action is to selectively inhibit the reuptake of the neurotransmitter serotonin (5 -HT) by binding to and blocking the SERT transporter on the presynaptic neuron. This blockade immediately increases the concentration of 5 -HT within the synaptic cleft, resulting in an amplified 5 -HT signal available to postsynaptic receptors and altering downstream signaling.

Modulation of Central Regulatory Pathways

Following the initial increase in synaptic 5 -HT, adaptive, long-term physiological changes occur. The sustained presence of 5 -HT leads to the desensitization and downregulation of specific serotonin autoreceptors over time, engaging neuronal feedback mechanisms. This chronic process influences activity within central neural circuits that receive 5 -HT projections, ultimately contributing to the adjustment of activity in defined physiological systems within targeted pathways.

Dosage and Administration Information

Ladose, which contains the active ingredient Fluoxetine Hydrochloride, is an orally administered medication available in various forms, including capsules, tablets, and an oral solution. The oral solution must be measured with a dedicated device, such as a marked spoon or syringe, to ensure accurate dosing. The medication may be taken with or without food, as its absorption is not significantly affected by meal timing.


Official Dosing and Frequency

Administration is typically once daily in the morning. However, doses exceeding 20 mg per day may be divided, and when used in combination with olanzapine, the medication is generally taken in the evening. For certain maintenance use in Major Depressive Disorder, a 90 mg delayed-release capsule is available, which is taken once weekly. This weekly capsule must be swallowed whole and should never be broken or crushed.

Standard Adult Starting Doses Indication Initial Dose Maintenance Dose Range
Major Depressive Disorder (MDD) 20 mg once daily 20 mg to 60 mg daily
Panic Disorder 10 mg once daily 20 mg to 60 mg daily
Bulimia Nervosa Titration up to 60 mg daily 60 mg daily

Usage Adjustments and Duration

Dose adjustments are made gradually after several weeks of treatment (e.g., 3 to 4 weeks for MDD) to achieve the lowest effective regimen. Treatment for MDD is typically maintained for at least six months following symptomatic recovery. Specific adjustments are mandated for certain patient populations; for instance, a lower or less frequent dosage is advised for patients with hepatic impairment.

Recent Clinical Evidence

Ladose: Recent Clinical Evidence

Research Focus and Findings on Efficacy

Research explored the drug's effect on mood and pain perception pathways in relation to patient outcomes.

  • Core Efficacy Trial (Phase 3 RCT) A large-scale Phase 3 Randomized Controlled Trial (RCT) examined changes in patient outcomes in this condition.
  • Main Findings The study found that the drug group had lower primary symptom scores over 12 weeks compared to the placebo group. This finding provided data for the drug's use in management over this timeframe.
  • Combination Therapy Research Other research evaluated whether adding this drug affected pain scores when combined with standard therapy. The findings of one meta-analysis suggested that the addition was associated with improved scores compared to standard therapy alone, though it is not yet clear whether this finding is conclusive.

Safety and Tolerability Profile

Studies on the drug’s safety profile primarily focused on short-term adverse events and specific patient populations.

  • General Side Effect Profile Research examined the frequency and type of adverse events, including fatigue, dry mouth, and nausea. Reports on the trials' safety analysis suggested that severe side effects leading to discontinuation were uncommon.
  • Dose-Response and Safety One trial evaluated whether higher doses were associated with more frequent side effects. A clear difference in adverse event frequency between doses was not demonstrated.
  • Specific Populations Research examined the drug's use in people with mild kidney impairment and excluded participants with severe impairment. The body of evidence for use in children and pregnant individuals is based on post-marketing case reports.

Time Course of Action

The evidence explored the time course of symptom changes in patients. One open-label study reported that changes in symptom scores were measurable within the first week of treatment initiation in a subset of participants. Findings were mixed across trials regarding the time to maximal observed benefit.

Key Studies & References

  1. Potential adverse events of fluoxetine: a real-world study based on the FAERS database (Example Safety Monitoring Data)

Frequently Asked Questions (FAQ)

Common questions about Ladose (FAQ)


Q: Does Ladose interact with common over-the-counter pain relievers like ibuprofen or aspirin?

A: Regulatory documents indicate that taking Ladose alongside Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which include common pain relievers like ibuprofen and aspirin, may increase the risk of bleeding events.

Q: Is there a risk of increased bleeding while taking Ladose, especially with other medicines?

A: Official information states that Ladose is associated with a risk of abnormal bleeding/hemorrhage, and this risk is further potentiated when combined with other medicines that affect hemostasis (the body's process of stopping blood flow).

Q: Are there any specific supplements or herbal remedies that should be avoided with Ladose?

A: Official safety information specifies that the herbal supplement St. John’s Wort should be avoided because its use alongside Ladose may increase the chances of developing a serious condition called Serotonin Syndrome.

Q: What are the known interactions between Ladose and triptans used for migraines?

A: The official product information notes that taking Ladose with migraine medications called triptans increases the risk of Serotonin Syndrome. This is due to the combined serotonergic activity, meaning both medicines affect the same brain chemical, serotonin.

Q: What kind of studies have examined the long-term use of Ladose?

A: The official duration for treatment in Major Depressive Disorder is often maintained for at least six months following recovery. While studies frequently focus on this timeframe, some regulatory patient documents indicate there are no known problems associated with its long-term use when the medication is taken as directed.

Q: Is Ladose considered a common or first-choice medicine for anxiety?

A: According to the official product label, Ladose is approved for the treatment of Panic Disorder, which is a condition classified within the anxiety spectrum. This designation establishes its use for specific anxiety-related conditions.

Q: Is it true that Ladose can lead to weight loss instead of weight gain?

A: Clinical trial data summaries report that a small amount of weight loss has been observed in some patients, particularly in the short-term. This may be related to temporary common side effects that can occur early in treatment, such as a decreased appetite or nausea.

Q: Is it generally better to take Ladose in the morning or at night?

A: The medication is typically administered once daily. The dose is typically taken in the morning to help minimize the common side effect of insomnia (difficulty sleeping).

Q: What happens if a dose of Ladose is missed?

A: General patient guidelines note that if a dose is missed, it should generally be skipped to avoid taking double or extra amounts.

Q: Is it normal to feel more anxious or restless during the first few weeks on Ladose?

A: Anxiety, nervousness, and restlessness are listed in official documents as common side effects of the medication. These effects are often reported when treatment is first started or following an adjustment to the dose.

Q: What is Serotonin Syndrome and what are the signs to watch out for while taking Ladose?

A: The official label describes Serotonin Syndrome as a potentially serious reaction caused by too much serotonin activity. Official product information notes that signs can include confusion, agitation, a fast heartbeat, high fever, shivering, excessive sweating, or muscle rigidity.

Q: Is Ladose safe to take during pregnancy, based on official information?

A: Official information indicates that use during pregnancy may be considered only if the potential benefit justifies the potential risks to the fetus. Warnings include the potential for the baby to experience short-term withdrawal symptoms or breathing problems if the medication is taken in the weeks leading up to delivery.

Q: What are the official recommendations regarding breastfeeding while taking Ladose?

A: Official information confirms that the active ingredient passes into breast milk in small amounts. While some regulatory bodies advise that breastfeeding is generally not recommended, decisions regarding use are conditional on the healthcare provider's assessment of the baby's health and the potential benefits.

Q: Can Ladose be used in children or adolescents, and for which conditions is it approved?

A: Yes, Ladose is approved for use in younger populations for specific conditions. It is approved for Obsessive-Compulsive Disorder (OCD) starting from age 7 and Major Depressive Disorder (MDD) starting from age 8.

Q: Does Ladose have any specific warnings for people over the age of 65?

A: Official safety documents note that older adults, particularly those over age 65, are at a higher risk for developing low blood sodium levels (hyponatremia) and potentially an increased risk of fractures with long-term use.

Q: What is the risk of a person with no history of bipolar disorder developing a manic episode on Ladose?

A: The official product label includes a warning that treatment may cause the activation of mania or hypomania. This warning applies to patients being treated for Major Depressive Disorder, though the risk for those with no prior history is not quantified.

Q: Can Ladose cause a person's blood pressure or heart rhythm to change?

A: Regulatory documents indicate that the medication is associated with the risk of QT prolongation, which is a type of heart rhythm problem. Changes in blood pressure are also listed as a symptom associated with the serious condition of Serotonin Syndrome.

Q: Does Ladose have a risk of causing low sodium levels (hyponatremia)?

A: Yes, the medication carries a risk of causing a low concentration of sodium in the blood, a condition called hyponatremia. This risk is specifically highlighted in official documents for older adults.

Q: Does Ladose affect blood sugar levels, and is it a concern for people with diabetes?

A: Official patient information notes that the medicine may affect blood sugar levels. Official patient information notes that diabetic patients may wish to discuss monitoring blood sugar levels with their healthcare provider.

Q: Are there specific food restrictions or dietary changes recommended while on Ladose?

A: Regulatory information indicates that the medication can be taken with or without food. There are no known effects of food on how the medicine works, and no specific dietary restrictions are recommended.

Q: Can Ladose cause unusual bruising or bleeding from the gums?

A: The risk of abnormal bleeding events means that bruising more easily than usual, and a tendency for nosebleeds or bleeding gums, are noted as possible physical manifestations associated with this risk.

Q: Can Ladose cause confusion or problems with memory?

A: Official adverse event listings include confusion and difficulty with concentration or memory problems as potential side effects. These are also noted as possible symptoms of low blood sodium levels (hyponatremia).

Q: How does Ladose affect motor skills or alertness for driving?

A: The medicine may cause side effects such as drowsiness, dizziness, and affect coordination or reaction time. Official guidance notes that patients should be aware that these effects may impair the ability to drive or operate machinery.

Q: Does Ladose have any effect on bone density or risk of fractures?

A: Official safety information notes that this class of medication may be associated with low bone mineral density and an increased risk of fractures (bone breaks). This risk is noted to be higher in older adults and with long-term use.

Q: Does Ladose carry a risk of seizures or fits?

A: Yes, regulatory documents list seizures as a rare, serious adverse event. They are also noted as a possible complication of serious side effects like Serotonin Syndrome or severe low blood sodium levels.

Q: What is the typical timeframe for initial side effects to improve after starting Ladose?

A: Official patient information notes that many common side effects, such as headache, nausea, and dry mouth, will often begin to improve over the first week or two as the patient continues to take the medication.

Q: What are the symptoms of stopping Ladose too quickly?

A: Official patient guidance indicates that stopping the medication abruptly may result in withdrawal symptoms. These symptoms can include irritability, nausea, dizziness, vomiting, nightmares, headache, and/or a prickling or tingling sensation (paresthesias).

Q: What kind of eye-related side effects, like glaucoma, are mentioned in the safety information for Ladose?

A: A rare but serious eye-related side effect noted in the official safety information is angle closure glaucoma. Symptoms of this condition include sudden eye pain or significant changes in vision.

Q: Is Ladose used for premenstrual dysphoric disorder (PMDD)?

A: Yes, according to the official product label, Ladose is FDA-approved for the treatment of Premenstrual Dysphoric Disorder (PMDD).

How should Ladose be stored and disposed of?

How to Store and Dispose of Ladose?

Ladose (Fluoxetine) must be stored and handled according to specific conditions to maintain product stability, as documented in official regulatory labeling.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). Brief excursions up to 30 C are permitted.
Protection Keep the medication in a tightly closed container and protect from moisture and light.
Safety The product must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Ladose must be disposed of following local requirements. Patients should utilize drug take-back programs if available, or follow household trash disposal procedures for non-flushable medicines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ladose found in:

A-Z Index: